CALGARY, Alberta, July 27, 2011 /PRNewswire/ -- Fero Industries, Inc. (OTCQB: FROI) (the “Company”) is pleased to report that Merck S.A. de C.V. has increased its Sucanon® promotional campaign across Mexico to include physician distributed sample packages. Four tablet sample packages of Sucanon® will be provided to patients at no-cost based on the physician’s discretion to raise awareness and encourage long-term customer acceptance of the product.
“The industry standard practice of providing no-cost samples to select patients through licensed physicians is the most cost-effective way for us reach and directly influence our potential Sucanon® user base,” said Mr. Luis M. Lopez, Chief Operating Officer of Fero Industries, Inc., and President of Pharmaroth S.A., the Company’s Mexican subsidiary. “The four tablet -- two day supply will be more than enough to provide each pre-diabetic or type-2 diabetic patient an immediate sense of the positive effects of adding Sucanon® to their daily treatment. We expect many of them will become long-term Sucanon® users.”
Sucanon® is approved as an over-the-counter (“OTC”) remedy for type-2 diabetes by regulatory authorities in Mexico and is distributed there under an exclusive agreement with Merck S.A. de C.V. (Merck S.A. de C.V. is the Mexico and Latin America sales and marketing organization of German pharmaceutical and chemical giant, Merck KGaA.)
Commercial sales of Sucanon® began in January 2011 in Mexico. Mexico has one of the largest and fastest growing diabetic populations in the world, estimated at 15% of the total population. This indicates over 16 million diagnosed cases of diabetes, up seven fold since 1990. Diabetes is now the leading cause of death in Mexico and costs the country more than one-third of its total public health care budget annually.
About Sucanon®
Sucanon® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called “insulin sensitizers”. Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizers lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.
For further information regarding Sucanon®, please visit the Fero Industries, Inc., website at www.feroindustries.com, email us at info@feroindustries.com, or call toll-free (855) 543-4900.
About Fero Industries, Inc.
Fero Industries, Inc. (OTCQB: FROI) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for type-2 diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. Fero’s strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
For investor relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462
Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Fero Industries, Inc. (the Company) to be materially different from those expressed or implied by such forward-looking statements.
The Company’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors discussed in the Company’s periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov under “Search for Company Filings”.
SOURCE Fero Industries, Inc.
